Skip to main content
SpringerLink
Log in

Repeated responses of an elderly patient with high-risk myelodysplastic syndrome to sequential therapy with tipifarnib, 5-azacitidine, and decitabine

  • Letter to the Editor
  • Published:
Annals of Hematology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Fenaux P, Raza P, GJi Muft, Aul C, Germing U, Kantarijan H, Cripe L, Kerstens R, De Porre P, Kurzrock R (2007) A multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediate to high risk mds. Blood 109:4158–4163. doi:10.1182/blood-2006-07-035725

    Article  PubMed  CAS  Google Scholar 

  2. Fenaux P, Mufti GJ, Santini V, Finelli C, Giagounidis A, Schoch R, List AF, Gore SD, Seymour JF, Hellstrom-Lindberg E, Bennet JM, Byrd JC, Backstrom JT, Zimmermann LS, McKenzie DR, Beach CL, Silverman LR (2007) Azacitidine treatment prolongs overall survival in higher-risk MDS patients compared with conventional care regimes: results of the aza-001 phase III study. Blood 110:817. Abstract

    Google Scholar 

  3. Strupp C, Germing U, Aivado M, Misgeld E, Haas R, Gattermann N (2002) Thalidomide for the treatment of patients with myelodysplastic syndromes. Leukemia 16:1–6. doi:10.1038/sj.leu.2402330

    Article  PubMed  CAS  Google Scholar 

  4. Raza A, Meyer P, Dutt D (2001) Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. Blood 98:958–965. doi:10.1182/blood.V98.4.958

    Article  PubMed  CAS  Google Scholar 

  5. Musto P (2004) Thalidomide therapy for myelodysplastic syndromes: current status and future perspectives. Leuk Res 28:325–332. doi:10.1016/j.leukres.2003.08.007

    Article  PubMed  CAS  Google Scholar 

  6. Beaupre DM, Kurzrock R (1999) Ras and leukemia: from basic mechanisms to gene-directed therapy. J Clin Oncol 17:1071

    PubMed  CAS  Google Scholar 

  7. Ashar HR, James L, Gray K, Carr D, Black S, Armstrong L, Bishop WR, Kirschmeier P (2000) Farnesyl transferaseinhibitors block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microtubules. J Biol Chem 275(39):30451–30457. doi:10.1074/jbc.M003469200

    Article  PubMed  CAS  Google Scholar 

  8. Kurzrock R, Kantarijan HM, Blascovich MA, Bucher C, Verstovsek S, Wright JJ, Pilat SR, Cortes JE, Estey EH, Giles FJ, Beran M, Sebti SM (2008) Phase I Study of alternate-week administration of tipifarnib in patients with MDS. Clin Cancer Res 14:509–514. doi:10.1158/1078-0432.CCR-07-1532

    Article  PubMed  CAS  Google Scholar 

  9. Silverman LR, Holland JF, Demakos EP (1994) Azacitidine (Aza C) in myelodysplastic syndromes (MDS), CALGB studies 8421 and 8921. Ann Hematol 68:A12

    Google Scholar 

  10. Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Holland JC, Odchimar-Reissig R, Stone RM, Nelson D, Powell BL, DeCastro CM, Ellerton J, Larson RA, Schiffer CA, Holland JF (2002) Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 20:2429–2440. doi:10.1200/JCO.2002.04.117

    Article  PubMed  CAS  Google Scholar 

  11. Kantarijan H, Issa JP, Rosenfeld CS, Bennett JM, Albitar M, DiPersio J, Klimek V, Slack J, de Castro C, Ravandi F, Helmer R 3rd, Shen L, Nimer SD, Leavitt R, Raza A, Saba H (2006) Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 106:1794–1803. doi:10.1002/cncr.21792

    Article  Google Scholar 

  12. Kantarijan H, Oki Y, Garcia-Manero G, Huang X, O'Brien S, Cortes J, Faderl S, Bueso-Ramos C, Ravandi F, Estrov Z, Ferrajoli A, Wierda W, Shan J, Davis J, Giles F, Saba HI, Issa JP (2007) Results of a randomized study of 3 schedules of low-dose decitabine in higher risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 109:52–57. doi:10.1182/blood-2006-05-021162

    Article  Google Scholar 

  13. Wijermans PW, Krulder JW, Huijgens PC, Neve P (1997) Continuous infusion of low-dose 5-Aza-2´-deoxycytidine in elderly patients with high-risk myelodysplastic syndrome. Leukemia 11:S19–S23. doi:10.1038/sj.leu.2400526

    Article  PubMed  Google Scholar 

  14. Wijermans PW, Lübbert M, Verhoef G, Bosly A, Ravoet C, Andre M, Ferrant A (2000) Low-dose 5-Aza-2´-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J Clin Oncol 18:956–962

    PubMed  CAS  Google Scholar 

  15. Borthakur G, Ahdab SE, Ravandi F, Faderl S, Ferrajoli A, Newman B, Issa JP, Kantarjian H (2008) Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine. Leuk Lymphoma 49(4):690–695. doi:10.1080/10428190701882146

    Article  PubMed  CAS  Google Scholar 

  16. Kuendgen A, Strupp C, Aivado M, Bernhardt A, Hildebrandt B, Haas R, Germing U, Gattermann N (2004) Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid. Blood 104:1266–1269. doi:10.1182/blood-2003-12-4333

    Article  PubMed  CAS  Google Scholar 

  17. Kuendgen A, Gattermann N (2007) Valproic acid for the treatment of myeloid malignancie. Cancer 110:943–995. doi:10.1002/cncr.22891

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgement

M. I. was responsible for all phases of the manuscript preparation and submission. K. A. and G. U. were responsible for manuscript conception, critical input, and review of the draft and final version of the manuscript. H. K. and B. S. performed data assembly. G. N. and H. R. gave final approval. The final version was approved by all authors. K. A. and G. N. received speakers honorarium from Celgene. G. U. received speakers honorarium and research support from Celgene and Janssen-Cilag.

Author information

Authors and Affiliations

  1. Department of Haematology, Oncology and Clinical Immunology, University Hospital of Düsseldorf, Moorenstrasse 5, 40225, Düsseldorf, Germany

    Isabel Möller, Sabine Blum, Norbert Gattermann, Rainer Haas, Kerstin Habersang, Ulrich Germing & Andrea Kuendgen

Authors
  1. Isabel Möller
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sabine Blum
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Norbert Gattermann
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Rainer Haas
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kerstin Habersang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ulrich Germing
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Andrea Kuendgen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Isabel Möller.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Möller, I., Blum, S., Gattermann, N. et al. Repeated responses of an elderly patient with high-risk myelodysplastic syndrome to sequential therapy with tipifarnib, 5-azacitidine, and decitabine. Ann Hematol 88, 1141–1144 (2009). https://doi.org/10.1007/s00277-009-0730-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-009-0730-x

Keywords

Search

Navigation